MedTrace Logo

Quality of Life Study of Helixate NexGen

NCT01053715 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2015-03-20

No results posted yet for this study

Summary

The aim of this study is to describe Health Related Quality of Life (HRQoL) in adolescents and adults with Hemophilia A treated prophylactically or on-demand with Helixate NexGen. The study will also assess the kinds of determinants, including key transitional life events, that might impact HRQoL in this patient population.

Conditions

Sponsors & Collaborators

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • Robert Klamroth, MD · Hämophiliezentrum, Vivantes-Klinikum im Friedrichshain Zentrum für Gefäßmedizin, Berlin

  • Alessandro Gringeri, MD · I.R.C.C.S. Fondazione Ospedale Maggiore Policlinico, Milan

Eligibility

Min Age
14 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01053715 on ClinicalTrials.gov